nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-219-11-130-137nogr-2608Research ArticleСтатьиГиперурикемия, подагра и патология пищеварительной системы: общие звенья патогенезаHyperuricemia, gout and digestive system pathology: common links of pathogenesishttps://orcid.org/0000-0002-6547-9425КонышкоН. А.KonyshkoN. A.nkonyshko@yandex.ruhttps://orcid.org/0000-0002-3748-8180МорозоваТ. Е.MorozovaT. E.noemail@neicon.ruhttps://orcid.org/0000-0001-8040-3704ЦуркоВ. В.TsurkoV. V.noemail@neicon.ruhttps://orcid.org/0009-0002-1915-1127КонышкоГ. С.KonyshkoG. S.noemail@neicon.ruПервый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияFirst Sechenov Moscow state medical UNIVERSITY of the Ministry of health of Russia (Sechenov University)Russian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова»РоссияPirogov Russian National Research Medical University (RNRMU)Russian FederationФГБОУ ВО Смоленский государственный медицинский университетРоссияSmolensk State Medical University of the Ministry of Health of RussiaRussian Federation202326032024011130137Copyright © Конышко Н.А., Морозова Т.Е., Цурко В.В., Конышко Г.С., 20242024Конышко Н.А., Морозова Т.Е., Цурко В.В., Конышко Г.С.Konyshko N.A., Morozova T.E., Tsurko V.V., Konyshko G.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2608

Цель: изучить и представить современные данные о прямых и опосредованных клинико-патогенетических взаимосвязях метаболизма пуриновых соединений с физиологическими и патологическими процессами мочевыделительной и пищеварительной систем в условиях нормального уровня мочевой кислоты, а также при гиперурикемии и подагре. Материал и методы. Проведен комплексный анализ доступных современных научных официальных источников и нормативных документов за период последнего десятилетия в базах Scopus, PubMed.com., E-library. Заключение. На основании данных современной научной литературы и многочисленных изысканий, можно говорить о наличии патогенетической взаимосвязи между уровнем мочевой кислоты и поражением органов мочевыделительной и пищеварительной систем.

The aim: to study and present scientists opinions on the direct and indirect clinical and pathogenetic purine compounds metabolism relationships with the digestive system physiological and pathological processes in normal uric acid levels conditions and in hyperuricemia and gout cases. Material and methods. A comprehensive analysis of available modern scientific official sources and regulatory documents for the last decade in the Scopus, PubMed.com, E-library databases. Conclusion. Based on the modern scientific literature data and numerous studies, we can say that there is a pathogenetic relationship between the level of uric acid and the digestive organs defeat.

гиперурикемияподаграпищеварительная системаpurine basishyperuricemiagoutdigestive systemReferencesXu L., Shi Y., Zhuang S. Recent advances on uric acid transporters. Oncotarget. 2017 Aug 10;8(59):100852-100862. doi: 10.18632/oncotarget.20135.Xu L., Shi Y., Zhuang S. Recent advances on uric acid transporters. Oncotarget. 2017 Aug 10;8(59):100852-100862. doi: 10.18632/oncotarget.20135.Bhatnagar V., Richard E.L., Wu W. Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling. Clin Kidney J. 2016 Jun;9(3):444-53. doi: 10.1093/ckj/sfw010.Bhatnagar V., Richard E.L., Wu W. Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling. Clin Kidney J. 2016 Jun;9(3):444-53. doi: 10.1093/ckj/sfw010.Nigam S.K., Bhatnagar V. The systems biology of uric acid transporters: the role of remote sensing and signaling. Curr Opin Nephrol Hypertens. 2018 Jul;27(4):305-313. doi: 10.1097/MNH.0000000000000427.Nigam S.K., Bhatnagar V. The systems biology of uric acid transporters: the role of remote sensing and signaling. Curr Opin Nephrol Hypertens. 2018 Jul;27(4):305-313. doi: 10.1097/MNH.0000000000000427.Li X., Yan Z., Tian J. Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models. Ann Clin Lab Sci. 2019 Ноя; 49 (6):756-762.Li X., Yan Z., Tian J. Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models. Ann Clin Lab Sci. 2019 Ноя; 49 (6):756-762.Dong Y., Zhao T., Ai W. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019). Expert Opin Ther Pat. 2019 Nov;29(11):871-879. doi: 10.1080/13543776.2019.1676727.Dong Y., Zhao T., Ai W. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019). Expert Opin Ther Pat. 2019 Nov;29(11):871-879. doi: 10.1080/13543776.2019.1676727.Chen M., Lu X., Lu C., Shen N. Soluble uric acid increases PDZK1 and ABCG2 expression in human intestinal cell lines via the TLR4-NLRP3 inflammasome and PI3K/Akt signaling pathway. Arthritis Res Ther. 2018 Feb 7;20(1):20. doi: 10.1186/s13075-018-1512-4.Chen M., Lu X., Lu C., Shen N. Soluble uric acid increases PDZK1 and ABCG2 expression in human intestinal cell lines via the TLR4-NLRP3 inflammasome and PI3K/Akt signaling pathway. Arthritis Res Ther. 2018 Feb 7;20(1):20. doi: 10.1186/s13075-018-1512-4.Fujita K., Ichida K. ABCG2 as a therapeutic target candidate for gout. Expert Opin Ther Targets. 2018 Feb;22(2):123-129. doi: 10.1080/14728222.2018.1420167.Fujita K., Ichida K. ABCG2 as a therapeutic target candidate for gout. Expert Opin Ther Targets. 2018 Feb;22(2):123-129. doi: 10.1080/14728222.2018.1420167.Toyoda Y., Mančíková A., Krylov V. Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort. Cells. 2019 Apr 18;8(4). pii: E363. doi: 10.3390/cells8040363.Toyoda Y., Mančíková A., Krylov V. Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort. Cells. 2019 Apr 18;8(4). pii: E363. doi: 10.3390/cells8040363.Tanaka M., Fukui M., Kuroda M. Pepsinogen I/II ratio is related to glucose, triacylglycerol, and uric acid levels. Nutrition. 2012. Apr;28(4):418-21. doi: 10.1016/j.nut.2011.09.006.Tanaka M., Fukui M., Kuroda M. Pepsinogen I/II ratio is related to glucose, triacylglycerol, and uric acid levels. Nutrition. 2012. Apr;28(4):418-21. doi: 10.1016/j.nut.2011.09.006.Fujita K., Ichida K. ABCG2 as a therapeutic target candidate for gout. Expert Opin Ther Targets. 2018 Feb;22(2):123-129. doi: 10.1080/14728222.2018.1420167.Fujita K., Ichida K. ABCG2 as a therapeutic target candidate for gout. Expert Opin Ther Targets. 2018 Feb;22(2):123-129. doi: 10.1080/14728222.2018.1420167.Reginato A.M., Mount D.B., Yang I., Choi H.K. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2012 Oct;8(10):610-21. doi: 10.1038/nrrheum.2012.144.Reginato A.M., Mount D.B., Yang I., Choi H.K. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2012 Oct;8(10):610-21. doi: 10.1038/nrrheum.2012.144.Boffetta P., Nordenvall C., Nyrén O., Ye W. A prospective study of gout and cancer. Eur J. Cancer Prev. 2009 Apr; 18(2):127-32. doi: 10.1097/CEJ.0b013e328313631a.Boffetta P., Nordenvall C., Nyrén O., Ye W. A prospective study of gout and cancer. Eur J. Cancer Prev. 2009 Apr; 18(2):127-32. doi: 10.1097/CEJ.0b013e328313631a.Wang W., Xu D., Wang B. Increased Risk of Cancer in relation to Gout: A Review of Three Prospective Cohort Studies with 50,358 Subjects. Mediators Inflamm. 2015;2015:680853. doi: 10.1155/2015/680853.Wang W., Xu D., Wang B. Increased Risk of Cancer in relation to Gout: A Review of Three Prospective Cohort Studies with 50,358 Subjects. Mediators Inflamm. 2015;2015:680853. doi: 10.1155/2015/680853.Chuang J.P., Lee J.C., Leu T.H. Association of gout and colorectal cancer in Taiwan: a nationwide population-based cohort study. BMJ Open. 2019 Oct 9;9(10):e028892. doi: 10.1136/bmjopen-2019-028892.Chuang J.P., Lee J.C., Leu T.H. Association of gout and colorectal cancer in Taiwan: a nationwide population-based cohort study. BMJ Open. 2019 Oct 9;9(10):e028892. doi: 10.1136/bmjopen-2019-028892.Liu X., Lv Q., Ren H. The altered gut microbiota of high-purine-induced hyperuricemia rats and its correlation with hyperuricemia. PeerJ. 2020 Mar 6;8:e8664. doi: 10.7717/peerj.8664.Liu X., Lv Q., Ren H. The altered gut microbiota of high-purine-induced hyperuricemia rats and its correlation with hyperuricemia. PeerJ. 2020 Mar 6;8:e8664. doi: 10.7717/peerj.8664.Pan L., Han P., Ma S. Abnormal metabolism of gut microbiota reveals the possible molecular mechanism of nephropathy induced by hyperuricemia. Acta Pharm Sin B. 2020 Feb;10(2):249-261. doi: 10.1016/j.apsb.2019.10.007.Pan L., Han P., Ma S. Abnormal metabolism of gut microbiota reveals the possible molecular mechanism of nephropathy induced by hyperuricemia. Acta Pharm Sin B. 2020 Feb;10(2):249-261. doi: 10.1016/j.apsb.2019.10.007.Guo Z., Zhang J., Wang Z.Intestinal Microbiota Distinguish Gout Patients from Healthy Humans. Sci Rep. 2016 Feb 8;6:20602. doi: 10.1038/srep20602.Guo Z., Zhang J., Wang Z.Intestinal Microbiota Distinguish Gout Patients from Healthy Humans. Sci Rep. 2016 Feb 8;6:20602. doi: 10.1038/srep20602.Wawro N., Amann U., Butt J. Helicobacter pylori Seropositivity: Prevalence, Associations, and the Impact on Incident Metabolic Diseases/Risk Factors in the Population-Based KORA Study. Front Public Health. 2019 Apr 24;7:96. doi: 10.3389/fpubh.2019.00096.Wawro N., Amann U., Butt J. Helicobacter pylori Seropositivity: Prevalence, Associations, and the Impact on Incident Metabolic Diseases/Risk Factors in the Population-Based KORA Study. Front Public Health. 2019 Apr 24;7:96. doi: 10.3389/fpubh.2019.00096.Longo-Mbenza B., Nkondi Nsenga J., Vangu Ngoma D. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics.Int J Cardiol. 2007 Oct 18;121(3):229-38. doi: 10.1016/j.ijcard.2006.12.003.Longo-Mbenza B., Nkondi Nsenga J., Vangu Ngoma D. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics.Int J Cardiol. 2007 Oct 18;121(3):229-38. doi: 10.1016/j.ijcard.2006.12.003.Herder C., Kannenberg J.M., Carstensen-Kirberg M. Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study. Cardiovasc Diabetol. 2017 Jan 31;16(1):17. doi: 10.1186/s12933-017-0498-6.Herder C., Kannenberg J.M., Carstensen-Kirberg M. Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study. Cardiovasc Diabetol. 2017 Jan 31;16(1):17. doi: 10.1186/s12933-017-0498-6.Guo Y., Li H., Liu Z. Impaired intestinal barrier function in a mouse model of hyperuricemia. Mol Med Rep. 2019 Oct;20(4):3292-3300. doi: 10.3892/mmr.2019.10586.Guo Y., Li H., Liu Z. Impaired intestinal barrier function in a mouse model of hyperuricemia. Mol Med Rep. 2019 Oct;20(4):3292-3300. doi: 10.3892/mmr.2019.10586.Zhao J., Shi P., Sun Y., Sun J. DHA protects against experimental colitis in IL-10-deficient mice associated with the modulation of intestinal epithelial barrier function. Br J Nutr. 2015 Jul;114(2):181-8. doi 10.1017/S0007114515001294.Zhao J., Shi P., Sun Y., Sun J. DHA protects against experimental colitis in IL-10-deficient mice associated with the modulation of intestinal epithelial barrier function. Br J Nutr. 2015 Jul;114(2):181-8. doi 10.1017/S0007114515001294.Weiwei Su, Bin Zhou, Guangming Qin. Association with nutritional and metabolic status in healthy people Low PG I/II ratio as a marker of atrophic gastritis. Medicine (Baltimore). 2018 May; 97(20): e10820. doi: 10.1097/MD.0000000000010820.Weiwei Su, Bin Zhou, Guangming Qin. Association with nutritional and metabolic status in healthy people Low PG I/II ratio as a marker of atrophic gastritis. Medicine (Baltimore). 2018 May; 97(20): e10820. doi: 10.1097/MD.0000000000010820.Lazebnik L.B., Alekseenko S.A., Lyalyukova E.A. et al. Recommendations for the management of primary patients with symptoms of dyspepsia. Experimental and clinical gastroenterology. 2018;5(153): 4-18. (In Russ.)@@ Лазебник Л.Б., Алексеенко С.А., Лялюкова Е.А. и соавт. Рекомендации по ведению первичных пациентов с симптомами диспепсии. Экспериментальная и клиническая гастроэнтерология. 2018;5(153):4-18.Lazebnik L.B., Alekseenko S.A., Lyalyukova E.A. et al. Recommendations for the management of primary patients with symptoms of dyspepsia. Experimental and clinical gastroenterology. 2018;5(153): 4-18. (In Russ.)@@ Лазебник Л.Б., Алексеенко С.А., Лялюкова Е.А. и соавт. Рекомендации по ведению первичных пациентов с симптомами диспепсии. Экспериментальная и клиническая гастроэнтерология. 2018;5(153):4-18.Eun Bae S., Hoon Lee J., Soo Park Y. Decrease of serum total ghrelin in extensive atrophic gastritis: comparison with pepsinogens in histological reference. Scand J Gastroenterol. 2016;51(2):137-44. doi: 10.3109/00365521.2015.1083049.Eun Bae S., Hoon Lee J., Soo Park Y. Decrease of serum total ghrelin in extensive atrophic gastritis: comparison with pepsinogens in histological reference. Scand J Gastroenterol. 2016;51(2):137-44. doi: 10.3109/00365521.2015.1083049.Cho J., Dalbeth N., Petrov M.S. Bidirectional relationship between gout and diabetes mellitus in individuals after acute pancreatitis: a nationwide cohort study. J. Rheumatol. 2019; 15. pii: jrheum.190487. doi: 10.3899/jrheum.190487.Cho J., Dalbeth N., Petrov M.S. Bidirectional relationship between gout and diabetes mellitus in individuals after acute pancreatitis: a nationwide cohort study. J. Rheumatol. 2019; 15. pii: jrheum.190487. doi: 10.3899/jrheum.190487.Gold-Smith F.D., Chand S.K., Petrov M.S. Post-pancreatitis diabetes mellitus: towards understanding the role of gastrointestinal motility. Minerva Gastroenterol Dietol. 2018 Dec;64(4):363-375. doi: 10.23736/S1121-421X.18.02507-2.Gold-Smith F.D., Chand S.K., Petrov M.S. Post-pancreatitis diabetes mellitus: towards understanding the role of gastrointestinal motility. Minerva Gastroenterol Dietol. 2018 Dec;64(4):363-375. doi: 10.23736/S1121-421X.18.02507-2.Lin K.C., Lin H.Y., Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Reumatol. 2000; 27 (6):1501-5.Lin K.C., Lin H.Y., Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Reumatol. 2000; 27 (6):1501-5.Min H.K., Kim H.R. Does normouricemic status in acute gouty arthritis really reflect a normal status? Consider confounders of serum levels of urate. Korean J Intern Med. 2020 Jan;35(1):62-64. doi: 10.3904/kjim.2019.423.Min H.K., Kim H.R. Does normouricemic status in acute gouty arthritis really reflect a normal status? Consider confounders of serum levels of urate. Korean J Intern Med. 2020 Jan;35(1):62-64. doi: 10.3904/kjim.2019.423.Han J., Song X., Lu S. Adolescent Hyperuricemia with Lipid Storage Myopathy: A Clinical Study. Med Sci Monit. 2019 Nov 30;25:9103-9111. doi: 10.12659/MSM.918841.Han J., Song X., Lu S. Adolescent Hyperuricemia with Lipid Storage Myopathy: A Clinical Study. Med Sci Monit. 2019 Nov 30;25:9103-9111. doi: 10.12659/MSM.918841.Thomas Bardin, Pascal Richette. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017; 15: 123. doi: 10.1186/s12916-017-0890-9PMCID: PMC5494879 PMID: 28669352.Thomas Bardin, Pascal Richette. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017; 15: 123. doi: 10.1186/s12916-017-0890-9PMCID: PMC5494879 PMID: 28669352.Sellin L1, Kielstein JT, de Groot K. Hyperuricemia - more than gout: Impact on cardiovascular risk and renal insufficiency. Z Rheumatol. 2015 May;74(4):322-8. doi: 10.1007/s00393-014-1481-1.Sellin L1, Kielstein JT, de Groot K. Hyperuricemia - more than gout: Impact on cardiovascular risk and renal insufficiency. Z Rheumatol. 2015 May;74(4):322-8. doi: 10.1007/s00393-014-1481-1.Major T.J., Dalbeth N., Stahl E.A., Merriman T.R. An update on the genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2018 Jun;14(6):341-353. doi: 10.1038/s41584-018-0004-x.Major T.J., Dalbeth N., Stahl E.A., Merriman T.R. An update on the genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2018 Jun;14(6):341-353. doi: 10.1038/s41584-018-0004-x.Thottam G.E., Krasnokutsky S., Pillinger M.H. Gout and Metabolic Syndrome: a Tangled Web. Curr Rheumatol Rep. 2017 Aug 26;19(10):60. doi: 10.1007/s11926-017-0688-y.Thottam G.E., Krasnokutsky S., Pillinger M.H. Gout and Metabolic Syndrome: a Tangled Web. Curr Rheumatol Rep. 2017 Aug 26;19(10):60. doi: 10.1007/s11926-017-0688-y.Konyshko N.A., Konyshko G.S. A systematic review of the molecular mechanisms of regulation of uric acid metabolism in the human intestine. Modern rheumatology. 2023;17(5):118-122. (In Russ.) doi: 10.14412/1996-7012-2023-5-118-122.@@ Конышко Н.А., Конышко Г.С. Систематический обзор молекулярных механизмов регуляции метаболизма мочевой кислоты в кишечнике человека. Современная ревматология. 2023;17(5):118-122. doi: 10.14412/1996-7012-2023-5-118-122.Konyshko N.A., Konyshko G.S. A systematic review of the molecular mechanisms of regulation of uric acid metabolism in the human intestine. Modern rheumatology. 2023;17(5):118-122. (In Russ.) doi: 10.14412/1996-7012-2023-5-118-122.@@ Конышко Н.А., Конышко Г.С. Систематический обзор молекулярных механизмов регуляции метаболизма мочевой кислоты в кишечнике человека. Современная ревматология. 2023;17(5):118-122. doi: 10.14412/1996-7012-2023-5-118-122.Richette P. et al. EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016; 0:1-14 doi: 10.1136/annrheumdis-2016-209707.Richette P. et al. EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016; 0:1-14 doi: 10.1136/annrheumdis-2016-209707.Nassonova V.A., Barskova V.G. Early diagnostic and treatment of gout - is scientifically based reguirements for improvement of labour and living prognosis of patients. Rheumatology Science and Practice. 2004;42(1):5-7. (In Russ.) doi: 10.14412/1995-4484-2004-1374.@@ Нассонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры - научно обоснованное требование улучшения трудового н жизненного прогноза больных. Научно-практическая ревматология. 2004;42(1):5-7. doi: 10.14412/1995-4484-2004-1374.Nassonova V.A., Barskova V.G. Early diagnostic and treatment of gout - is scientifically based reguirements for improvement of labour and living prognosis of patients. Rheumatology Science and Practice. 2004;42(1):5-7. (In Russ.) doi: 10.14412/1995-4484-2004-1374.@@ Нассонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры - научно обоснованное требование улучшения трудового н жизненного прогноза больных. Научно-практическая ревматология. 2004;42(1):5-7. doi: 10.14412/1995-4484-2004-1374.Stewart S., Yang KCK., Atkins K. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020 Feb 13;22(1):28. doi: 10.1186/s13075-020-2120-7.Stewart S., Yang KCK., Atkins K. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020 Feb 13;22(1):28. doi: 10.1186/s13075-020-2120-7.Abbott C.E., Xu R., Sigal S.H.Colchicine-Induced Hepatotoxicity. ACG Case Rep J. 2017; 4:e120. Epub 2017 Nov 22.doi: 10.14309 / crj.2017.120Abbott C.E., Xu R., Sigal S.H.Colchicine-Induced Hepatotoxicity. ACG Case Rep J. 2017; 4:e120. Epub 2017 Nov 22.doi: 10.14309 / crj.2017.120Mailloux R.J. Protein S-glutathionylation reactions as a global inhibitor of cell metabolism for the desensitization of hydrogen peroxide signals. Redox Biol. 2020 Mar 7;32:101472. doi: 10.1016/j.redox.2020.101472.Mailloux R.J. Protein S-glutathionylation reactions as a global inhibitor of cell metabolism for the desensitization of hydrogen peroxide signals. Redox Biol. 2020 Mar 7;32:101472. doi: 10.1016/j.redox.2020.101472.Yan J., Jiang J., He L. Mitochondrial superoxide/hydrogen peroxide: An emerging therapeutic target for metabolic diseases. Free Radic Biol Med. 2020 Mar 8;152:33-42. doi: 10.1016/j.freeradbiomed.2020.02.029.Yan J., Jiang J., He L. Mitochondrial superoxide/hydrogen peroxide: An emerging therapeutic target for metabolic diseases. Free Radic Biol Med. 2020 Mar 8;152:33-42. doi: 10.1016/j.freeradbiomed.2020.02.029.Wechalekar M.D., Vinik O., Moi J.H. The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. J. Rheumatol Suppl. 2014; 92:15-25. doi: 10.3899/jrheum.140458.Wechalekar M.D., Vinik O., Moi J.H. The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. J. Rheumatol Suppl. 2014; 92:15-25. doi: 10.3899/jrheum.140458.Shekelle P.G., Newberry S.J., FitzGerald J.D. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017 Jan 3;166(1):37-51. doi: 10.7326/M16-0461.Shekelle P.G., Newberry S.J., FitzGerald J.D. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017 Jan 3;166(1):37-51. doi: 10.7326/M16-0461.Zhang MY1, Niu JQ1, Wen XY1, Jin QL Liver failure associated with benzbromarone: A case report and review of the literature. World J Clin Cases. 2019 Jul 6;7(13):1717-1725. doi: 10.12998/wjcc.v7.i13.1717.Zhang MY1, Niu JQ1, Wen XY1, Jin QL Liver failure associated with benzbromarone: A case report and review of the literature. World J Clin Cases. 2019 Jul 6;7(13):1717-1725. doi: 10.12998/wjcc.v7.i13.1717.Iqbal U., Siddiqui H.U., Anwar H., Chaudhary A., Quadri A.A. Allopurinol-Induced Granulomatous Hepatitis: A Case Report and Review of Literature. J Investig Med High Impact Case Rep. 2017 Sep 8;5(3):2324709617728302. doi: 10.1177/2324709617728302.Iqbal U., Siddiqui H.U., Anwar H., Chaudhary A., Quadri A.A. Allopurinol-Induced Granulomatous Hepatitis: A Case Report and Review of Literature. J Investig Med High Impact Case Rep. 2017 Sep 8;5(3):2324709617728302. doi: 10.1177/2324709617728302.Chawla S.K., Patel H.D., Parrino G.R., Soterakis J., Lopresti P.A., D’Angelo W.A. Allopurinol hepatotoxicity. Case report and literature review. Arthritis Rheum. 1977 Nov-Dec;20(8):1546-9. doi: 10.1002/art.1780200817.Chawla S.K., Patel H.D., Parrino G.R., Soterakis J., Lopresti P.A., D’Angelo W.A. Allopurinol hepatotoxicity. Case report and literature review. Arthritis Rheum. 1977 Nov-Dec;20(8):1546-9. doi: 10.1002/art.1780200817.

The authors declare that there are no conflicts of interest present.